Piramal Pharma FY26: ₹8,869 cr revenue, board reset

Key update for investors

Piramal Pharma Limited has announced its financial results for the year ended March 31, 2026, alongside a set of board and management changes disclosed through stock exchange filings. The company reported standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore for FY2026.

Alongside the numbers, the company confirmed leadership continuity at the board level through re-appointments of executive and independent directors. It also announced a change in its Key Managerial Personnel, naming a new Company Secretary and Compliance Officer effective April 29, 2026. The disclosures matter because they combine audited annual performance indicators with governance updates that shape investor oversight under SEBI listing norms.

FY26 financial performance at a glance

On a standalone basis, Piramal Pharma reported profit after tax (PAT) of ₹700.01 crore for FY2026, compared with ₹691.40 crore in the previous year. This indicates a modest year-on-year improvement in standalone profitability, based on the figures disclosed.

On a consolidated basis, the company reported a net loss after tax of ₹325.94 crore for FY2026. The consolidated loss was stated to reflect various operational and exceptional items, including an impairment charge recognised during the year. The filing specifically highlighted an impairment charge of ₹175.82 crore.

Standalone numbers: revenue and profit trends

Standalone revenue for FY2026 stood at ₹4,782.01 crore. The standalone PAT for the year came in at ₹700.01 crore, compared with ₹691.40 crore in the previous year.

While the disclosure does not provide segment-level drivers in the text provided, the standalone profit comparison is a key reference point for investors tracking the India entity’s earnings. Standalone results often influence views on dividend capacity and domestic cash generation, even when consolidated performance is impacted by non-cash or group-level items.

Consolidated results: loss and the impairment charge

Consolidated revenue for FY2026 was ₹8,869.08 crore. Despite this topline, the company reported a consolidated net loss after tax of ₹325.94 crore.

A key item highlighted in the disclosure was the impairment charge of ₹175.82 crore recognised during the year. Impairment charges are typically non-cash accounting adjustments, but they can materially affect reported profitability and investor perception, particularly when they indicate reassessment of asset values or expected future cash flows. The company’s filing links the loss to operational and exceptional items, with impairment specifically called out.

Summary table: FY26 reported figures

Board and leadership re-appointments

Piramal Pharma said its Board of Directors approved several leadership transitions and re-appointments. Ms. Nandini Piramal has been re-appointed as Whole-Time Director, designated as Executive Director and Chairperson, for a further term of three years starting April 1, 2027.

The board also re-appointed Mr. Peter DeYoung as Whole-Time Director, designated as Executive Director, for a three-year term effective October 6, 2026. Such re-appointments are typically linked to continuity in strategy execution and oversight, and they are closely tracked by institutional investors for governance stability.

Independent directors: second-term approvals

The company disclosed that the board approved the re-appointment of independent directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five consecutive years, effective March 30, 2027. Independent director renewals are an important governance signal because they shape committee composition and board independence in listed companies.

Separately, the provided exchange updates also note that Mr. Subramanian Ramadorai ceased as an Independent Director with effect from February 9, 2026, on completion of his term.

Company secretary transition and compliance role

Piramal Pharma announced a change in its Key Managerial Personnel, with Mr. Maneesh Sharma appointed as the new Company Secretary and Compliance Officer effective April 29, 2026. He takes over from Ms. Pratibha Mishra, who served as the interim lead.

Company secretary and compliance officer appointments are material under listing regulations because the role is central to exchange filings, board processes, and compliance reporting.

Registered office address update in Mumbai

The company also disclosed an update to its registered office address in Mumbai, effective April 30, 2026. The new registered office will be at the Ananta Building, Piramal Corporate Park.

Registered office changes typically require regulatory filings and updated statutory records. For shareholders, it is also a practical update for formal correspondence and corporate documentation.

Board meeting context and trading window closure

The exchange communication referenced a board meeting scheduled on April 28, 2026 to consider and approve audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The text also notes a trading window closure from April 1, 2026 to April 30, 2026 (both days inclusive), consistent with insider trading compliance norms around results.

The company also scheduled an earnings conference call on April 29, 2026, providing dial-in access for investors and analysts to discuss quarterly and annual results.

Market snapshot included in disclosures

The provided market context also notes Piramal Pharma trading at ₹182, against a 52-week high of ₹268, and a 1-year return of -20%. These datapoints indicate the stock’s recent price performance in the period surrounding the results cycle, based on the text shared.

Timeline of key disclosed events

What to watch next

With FY2026 audited numbers and governance changes disclosed, investors typically focus on the reconciliation between standalone profitability and consolidated losses, especially where impairment is a significant contributor. They also watch for any follow-through in governance execution, including smooth compliance transitions and timely statutory updates following a registered office shift.

The next formal checkpoints are the company’s scheduled discussions around results and any further exchange disclosures tied to board decisions already referenced, including matters considered at the April 28, 2026 meeting.

Conclusion

Piramal Pharma’s FY2026 disclosures combine financial reporting and governance actions, with standalone PAT of ₹700.01 crore and a consolidated net loss of ₹325.94 crore that includes an impairment charge of ₹175.82 crore. The company has also confirmed board re-appointments, a new Company Secretary and Compliance Officer effective April 29, 2026, and a registered office change effective April 30, 2026. Investors will track subsequent filings and scheduled engagements linked to the audited results process.